Urinary system neoplasm

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

Researchers are testing a new cell therapy called ADI-270 in adults with clear cell renal cell carcinoma that has come back or stopped responding to standard treatments. ADI-270 uses engineered gamma-delta T cells that carry a chimeric receptor to seek out and attack cancer cells…

This early-phase trial is testing a therapy called anti-CD70 CAR-T cells in people with advanced kidney cancer that has not responded to standard treatments. The approach involves taking a patient's own immune cells, engineering them in a lab to recognize a protein called CD70 on…

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to c…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

This phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…

Researchers at Dana-Farber Cancer Institute are testing whether information from a bladder tumor's genes, combined with how the tumor responds to chemotherapy, can help doctors and patients decide between bladder-sparing chemoradiation and surgery to remove the bladder. The study…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…

This Phase III trial tests whether giving a highly targeted form of radiation (SAbR) before standard therapy (immunotherapy or targeted pills) helps people with kidney cancer that has spread to 2-5 spots in the body live longer. About 472 participants are randomly assigned to rec…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see w…

This study tests a new robotic surgery technique for kidney cancer that avoids clamping blood vessels and using stitches to close the kidney. The goal is to preserve as much kidney function as possible and reduce the risk of long-term kidney disease. About 59 adults with small ki…

This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests whether adding a third drug (relatlimab) to a standard two-drug combination (nivolumab and ipilimumab) works better for advanced kidney cancer that hasn't been treated before. About 15 adults with stage IV clear cell kidney cancer will receive either the three-dr…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

Researchers are studying eribulin mesylate, a chemotherapy drug, in people with urothelial cancer that has spread or cannot be removed by surgery, and who also have kidney problems. The trial has two parts: one to find the highest dose patients can tolerate, and another to see ho…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This trial tests an experimental drug called DS-6000a (also known as R-DXd) in people with advanced renal cell carcinoma (kidney cancer) and ovarian tumors. The main goals are to find a safe dose, identify side effects, and see if the drug can shrink tumors. Participants receive …

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This phase 2 trial tests whether giving focused radiation (SBRT) along with immunotherapy drugs (cemiplimab, with or without fianlimab) before bladder removal can safely shrink muscle-invasive bladder tumors. The study enrolls 44 patients who cannot or choose not to take standard…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This phase II trial tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib helps people with advanced papillary kidney cancer live longer without their disease getting worse. About 200 participants will receive either cabozantinib alone or cabo…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests a pill called erdafitinib in 20 people whose non-muscle invasive bladder cancer has returned after standard treatments like BCG. All participants have a specific change in the FGFR3 gene, which the drug targets. They take the pill for about a month before their s…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This trial tests a gene therapy called FE 999326 (nadofaragene firadenovec) in Japanese patients with high-grade non-muscle invasive bladder cancer that has not responded to BCG treatment. The therapy is given as a liquid instilled into the bladder through a catheter every three …

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called sacituzumab govitecan in people with advanced bladder cancer that has spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the cancer. About 827 adults with good organ function and a life expectancy o…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This phase 2 trial tests whether adding avelumab (an immunotherapy) to another anti-cancer drug (sacituzumab govitecan) can help prevent advanced bladder cancer from growing after initial chemotherapy. About 256 participants with locally advanced or metastatic urothelial carcinom…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase 3 trial tests two new approaches for high-risk bladder cancer that hasn't spread into the muscle. One group gets a drug called TAR-200 placed directly into the bladder plus an immunotherapy drug (cetrelimab). Another group gets TAR-200 alone. These are compared to the …

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…

This study tests a targeted cancer drug called erdafitinib, alone or combined with an immunotherapy (cetrelimab) and/or chemotherapy, in 125 people with advanced urothelial cancer that has spread. The goal is to find safe doses and see if the treatments shrink tumors. Participant…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This phase 2 trial tests a drug called erdafitinib in 239 people with advanced bladder cancer that has certain FGFR gene changes. The drug aims to shrink tumors by blocking signals that help cancer grow. Researchers are checking how well it works and what side effects occur.

This Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…

This Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…

This study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This phase 3 trial tests whether adding the immune-boosting drug nivolumab before and after kidney cancer surgery can prevent the cancer from coming back. About 819 patients with localized kidney cancer are randomly assigned to receive either surgery alone or surgery plus nivolum…

This study tests a drug called erdafitinib, placed directly into the bladder using a special delivery system, for people with non-muscle-invasive or muscle-invasive bladder cancer. The trial has four parts to find the best dose and check safety and effectiveness. About 235 partic…

This phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-stage study tests a new treatment called ALLO-316 for people with advanced or spreading clear cell kidney cancer who have already tried standard therapies like checkpoint inhibitors and VEGF inhibitors. The treatment uses specially designed immune cells from a donor to…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This large Phase 3 trial is testing whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy can help people with advanced bladder cancer that cannot be removed by surgery. Over 1,200 participants worldwide are receiving either che…

This Phase 3 trial tests whether adding belzutifan or quavonlimab to a standard immunotherapy (pembrolizumab) and targeted therapy (lenvatinib) works better for advanced clear cell kidney cancer. About 249 Chinese patients who haven't had prior treatment will be randomly assigned…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This phase 3 trial asks whether removing the bladder right away is as effective as giving chemotherapy first, for patients with muscle-invasive bladder cancer who have no visible tumor left after a thorough biopsy. About 236 adults will be randomly assigned to either surgery alon…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This study tests if adding another drug (belzutifan or quavonlimab) to a standard two-drug treatment can help people with advanced clear cell kidney cancer live longer or stop their cancer from growing. About 1,650 adults who have not had prior treatment for advanced disease will…

This study looks at whether using ureteral stents (small tubes) after bladder cancer surgery leads to more or fewer problems than not using them. About 190 adults having their bladder removed will be randomly assigned to get stents or not. The main goal is to see who ends up back…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 85 adults with advanced kidney cancer that could not be removed by surgery. The goal was to see if stopping nivolumab early in those who responded well, or adding ipilimumab in those who did not, could better…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This trial investigates whether combining two drugs—BCG and gemcitabine—can safely and effectively treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that has come back after previous BCG treatment. Participants receive BCG directly into the bladder …

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) to the immunotherapy drug nivolumab can prevent high-risk bladder cancer from coming back after surgery. About 62 participants will receive either the combination or nivolumab alone. The st…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This large global trial is testing whether two experimental drugs—volrustomig (an immunotherapy) and casdatifan (a pill)—work better than the current standard immunotherapy combination for people with advanced clear cell kidney cancer. About 1,100 participants who have not had pr…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This study tests a drug called TOOKAD (padeliporfin) that is activated by light to destroy low-grade tumors in the kidney or ureter. About 100 adults with this rare cancer will receive the treatment in two phases, with follow-up for up to 4 years. The goal is to see if the therap…

This study is testing experimental combinations of drugs for people with advanced kidney cancer (clear cell type) that has gotten worse after initial treatment. The goal is to see if these combinations are safe and can shrink tumors. About 370 participants will be enrolled in thi…

This clinical trial is testing several new combinations of drugs for people with advanced kidney cancer that has spread. The study includes about 400 participants who have not had any prior treatment for their advanced disease. The goal is to see if these combinations are safe an…

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …

This phase 3 trial is testing whether a combination of the experimental drug XL092 and the immunotherapy nivolumab can help people with advanced non-clear cell kidney cancer live longer without their disease worsening. Participants have not received prior treatment for their adva…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This phase 2 trial is testing whether adding stereotactic body radiation therapy (SBRT) to high-dose Interleukin-2 (IL-2) can improve response rates in people with metastatic renal cell carcinoma. All participants receive IL-2, and half also get two doses of SBRT to a few tumor s…

This study tests whether combining a targeted drug called disitamab vedotin with BCG therapy can improve outcomes for people with HER2-positive high-risk non-muscle invasive bladder cancer. The drug is given intravenously every three weeks, while BCG is delivered directly into th…

This study tests an immunotherapy drug called camrelizumab, given directly into the bladder, for people with high-risk non-muscle invasive bladder cancer that did not respond to BCG treatment. The goal is to find a safe dose and see if it can prevent cancer from coming back or ge…

This study tests a treatment plan for people with muscle-invasive bladder cancer who want to avoid bladder removal. Participants receive chemotherapy plus an immunotherapy drug called tislelizumab, followed by a tailored course of radiation therapy. The goal is to see if this com…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer. About 1,063 participants will receive either the drug combo or standard care. The goal is to see i…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This early-stage trial is testing a new peptide vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab (Keytruda) in 30 adults with high-risk non-muscle invasive bladder cancer that did not respond to or could not tolerate standard BCG therapy. The vaccine is de…

This phase 3 trial tests whether a combination of enfortumab vedotin and pembrolizumab, given before and after bladder removal surgery, works better than standard chemotherapy for muscle-invasive bladder cancer. About 800 participants will be randomly assigned to one of the two t…

This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and preve…

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 partici…

This trial tests whether lab-grown miniature tumors, called organoids, can help choose the best chemotherapy for people with intermediate-risk bladder cancer. Tumor samples are taken during surgery and grown in the lab. After testing several drugs on the organoids, the most effec…

This phase 2 trial is testing whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent kidney cancer from coming back after surgery. About 272 people with high-risk kidney cancer will receive either the vaccine plus immunotherapy or…

This study tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder for people with non-muscle invasive bladder cancer. The goal is to see if this treatment can control or eliminate tumors, especially for those who cannot get stand…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bladder cancer that has not been treated before. Participants have a type of bladder cancer that has spread or cannot be removed by surgery and shows a protein c…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…

This trial tests a combination of two drugs—anlotinib (a pill that blocks blood vessel growth to tumors) and sintilimab (an IV immunotherapy that helps the immune system attack cancer cells)—as a first treatment for people with advanced non-clear cell renal cell carcinoma, a rare…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy in people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants whose cancer worsened after prior treatments will be randomly assigned to receive erdaf…

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This phase 3 trial tests whether adding two immunotherapy drugs—pembrolizumab and enfortumab vedotin—before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. The study includes patients who cannot take o…

This study tests a robotic-assisted surgery tool to remove bladder lesions. About 30 adults with small bladder tumors will undergo the procedure. The goal is to see if the robot helps remove the tumor in one piece with healthy tissue around it, which may improve diagnosis and red…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests a device that uses focused sound waves (histotripsy) to break apart kidney tumors without making any cuts. About 67 adults with a single small kidney mass (3 cm or less) that hasn't spread will be treated. The goal is to see if the tumors are completely gone afte…

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study looks at how well a combination of two drugs (enfortumab vedotin and pembrolizumab) works as a first treatment for people with advanced upper tract urothelial carcinoma, a rare cancer of the urinary tract. Researchers will track 50 patients in France to see how many re…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This study tests whether giving two drugs—nivolumab (immunotherapy) and cabozantinib (targeted therapy)—before removing the kidney can make all visible cancer disappear in people with advanced kidney cancer that has spread. About 38 adults with metastatic renal cell carcinoma wil…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This phase 3 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted therapy (enfortumab vedotin) works better than current standard care for people with muscle-invasive bladder cancer who cannot take or refuse cisplatin chemotherapy. A…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This phase 3 study tests whether a combination of two drugs, enfortumab vedotin and pembrolizumab, works better than standard chemotherapy for people with advanced urothelial cancer that has spread. About 886 participants who have not had prior treatment for their advanced cancer…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This early-phase trial is testing whether giving testosterone replacement therapy to men with low testosterone before and after major urologic surgery is safe and might improve recovery. Researchers will track quality of life, frailty, complications, hospital stay length, and rea…

This phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 28 adults with advanced clear cell kidney cancer that worsened after initial immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Participants receive treatment un…

This study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited …

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This phase 3 trial tests whether adding belzutifan to standard pembrolizumab after kidney cancer surgery can delay or prevent the cancer from coming back. About 1800 participants with clear cell renal cell carcinoma are randomly assigned to receive either belzutifan plus pembroli…

This phase 3 trial compares the experimental drug belzutifan to the standard drug everolimus in 755 people with advanced kidney cancer that has worsened after prior treatments. The goal is to see if belzutifan can better delay cancer growth and improve survival. Participants take…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase III trial tests whether an immune-enhancing nutritional supplement, taken before and after bladder cancer removal surgery, can reduce post-operative complications and infections. About 203 participants are randomly assigned to receive either the supplement or a placebo…

This phase 3 trial compares a combination of two drugs, belzutifan and lenvatinib, against the standard drug cabozantinib in 747 people with advanced kidney cancer that has worsened after initial treatment. The goal is to see if the combo can better slow cancer growth or improve …

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This early-phase study tests a new gene therapy for people with advanced clear cell kidney cancer. Doctors take a patient's own white blood cells, modify them in the lab to better attack cancer, and return them to the body. The main goals are to check safety and see if tumors shr…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests a minimally invasive procedure that blocks blood flow to kidney angiomyolipomas (non-cancerous tumors). The goal is to shrink the tumors and stop bleeding while preserving kidney function. Researchers will follow 50 patients for one year to check safety and effec…

This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.

This registry follows 750 patients with small kidney tumors who are not good candidates for surgery. They receive either cryotherapy (freezing) or radiofrequency ablation (heating) to destroy the tumor. Researchers will track survival, kidney function, and complications over time…

This phase 2 trial is testing whether the immunotherapy drug Keytruda (pembrolizumab) can help people with muscle-invasive bladder cancer avoid having their bladder removed. About 46 participants will receive two cycles of Keytruda, then doctors will check if the cancer has compl…

This study looks at adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) for people with advanced or metastatic bladder cancer that cannot be removed by surgery. Researchers want to see if giving the drugs in a different order—chemothera…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. …

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …

This phase II trial tests the immunotherapy drug pembrolizumab in 39 people with advanced adrenocortical carcinoma that cannot be removed by surgery. The study aims to see if the drug can shrink or control the cancer. Participants receive pembrolizumab and are monitored for tumor…

This study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests a device called GPX that blocks blood flow to tumors or other targeted areas. About 114 adults with conditions like kidney tumors or bone tumors will receive the treatment. The goal is to see if the device is safe and works well at reaching and blocking small blo…

This study tests whether the immunotherapy drug atezolizumab can delay or prevent bladder cancer from coming back after surgery. It includes 761 high-risk patients whose blood tests showed cancer DNA after bladder removal. Participants receive either atezolizumab or a placebo to …

This study compares two treatments for a rare type of urinary tract cancer. One group gets chemotherapy before surgery, the other has surgery alone. The goal is to see if chemo helps shrink the tumor and improve long-term outcomes. About 120 adults with high-risk, non-spread canc…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This phase III trial is testing whether a different strain of BCG (Tokyo-172) works better than the standard TICE strain for high-grade bladder cancer that hasn't spread into muscle. It also looks at whether giving a BCG vaccine under the skin before the usual bladder treatment h…

This study tests whether combining two drugs—serplulimab and fruquintinib—can prevent kidney cancer from returning after surgery in people with a rare, aggressive type called non-clear cell renal cell carcinoma. About 40 adults at high risk of recurrence will receive both drugs f…

This study tests a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread. The drug works in two ways: it helps the immune system attack cancer cells and blocks blood vessels that feed tumors. About 60 participants will receive the drug every…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…

This was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to …

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This early-phase trial tests whether combining two drugs—avelumab (an immunotherapy) and AVB-S6-500 (a targeted therapy)—is safe and can help people with advanced bladder cancer that has worsened after chemotherapy. Nineteen adults with inoperable or metastatic urothelial carcino…

This study planned to test a material called PuraBond that helps stop bleeding during robotic surgery for kidney cancer. The goal was to see if it works safely and helps the kidney heal. However, the study was withdrawn before any participants were enrolled.

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This study tests a new type of daily radiation therapy for muscle-invasive bladder cancer that adapts to changes in the body each day. The goal is to see if this approach lowers the chance of diarrhea and other bowel problems compared to standard radiation. About 110 adults with …

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This large Phase 3 study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding nivolumab to standard chemotherapy helps people with advanced bladder cancer live longer than chemotherapy alone. About 1,300 participants with untreated, inoperable or m…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This phase 2 trial is testing a radioactive drug called 177Lu-PSMA-617 (Pluvicto) in 24 people with advanced clear cell kidney cancer that shows a specific marker (PSMA). The drug is given by IV and aims to shrink tumors. Researchers are measuring how many patients respond and tr…

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could delay cancer growth better than sunitinib alone. About 1,069 adults with …

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study planned to test whether adding acarbose, a drug normally used for diabetes, could improve standard immunotherapy for advanced kidney cancer. The goal was to see if the combination was safe and affected gut bacteria. However, the trial was withdrawn before enrolling any…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This Phase 2 trial is testing a new combination of two immunotherapy drugs, botensilimab and balstilimab, against the standard combination of ipilimumab and nivolumab for people with advanced kidney cancer that has spread. The study plans to enroll 120 patients who have not had p…

This study looks at whether eating a diet rich in cruciferous vegetables (like broccoli, cauliflower, and cabbage) can help prevent bladder cancer from coming back in people with intermediate to very high-risk non-muscle invasive bladder cancer. About 250 participants will either…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase 2 trial tests two drugs, pembrolizumab and lenvatinib, in 30 adults with advanced adrenal cortical carcinoma that has worsened after standard chemotherapy. The goal is to see if the combination can shrink or slow the cancer. Participants receive the drugs intravenously…

This phase 3 trial tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment helps control high-risk non-muscle invasive bladder cancer better than BCG alone. Over 1,000 participants are enrolled, with some receiving the combination and others BCG only. The…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests a device called PROSENSE™ that freezes kidney tumors to destroy them. It involves 120 adults with small kidney cancers (up to 5 cm). The goal is to see if the freezing completely covers the tumor and prevents it from coming back over 5 years. The approach is mini…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This early-stage trial tests the safety of combining the immunotherapy drug pembrolizumab with radiation therapy for people with advanced bladder cancer. About 34 patients with either locally advanced or metastatic disease will receive pembrolizumab before and during radiation, t…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This study tests whether the immunotherapy drug nivolumab, given after standard chemo-radiation, can help prevent bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal…

This early-stage study tests a new drug called NYM096 in people with advanced clear cell kidney cancer that has spread. The study has two parts: first, using a low dose to see if it can light up tumors on scans, and second, giving higher doses to see if it can shrink tumors and f…

This study is for people with muscle-invasive bladder cancer that has gotten worse after earlier treatments. It tests several different drug combinations, chosen based on the specific genetic markers of each person's tumor. The main goal is to see if these combinations are safe a…

This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can prevent high-risk kidney cancer from coming back after surgery to remove the kidney. About 100 participants will receive the drug every three weeks for up to a year. Researchers will track how long they…

This phase 2 trial is testing whether a combination of chemotherapy, an immunotherapy drug called toripalimab, and radiation can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. About 71 adults with this type of bladder cancer will r…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to…

This study tests a drug called abemaciclib in 20 people with bladder cancer who cannot receive standard chemotherapy. Participants take the drug before their scheduled surgery to remove the bladder. Researchers will compare tumor samples taken before and after treatment to see ho…

This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming …

This study tests special blood-sparing techniques during surgery for advanced kidney cancer. The goal is to reduce the number of donor blood transfusions patients need. About 240 adults with large kidney tumors will be randomly assigned to receive either the blood-sparing protoco…

This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, fea…

This study tests if a subcutaneous (under-the-skin) injection of the drug nivolumab works as well as the standard intravenous (IV) infusion for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. About 681 participants who have already rec…

This phase 2 trial tests whether taking the drug axitinib for 8 weeks before surgery can shrink kidney tumors in people with clear cell renal cell carcinoma. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are too complex for t…

This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive ei…

This study tests a surgical navigation system called RUS NE that turns CT scans into 3D models to help guide robot-assisted kidney tumor removal. Researchers will compare outcomes in 80 patients who use the system versus those who don't, looking at how much tissue is removed and …

This early-stage trial tests whether taking capsules containing processed stool from healthy donors can prevent severe immune-related side effects in people with advanced kidney cancer receiving a combination of two immunotherapy drugs (ipilimumab and nivolumab). The study involv…

This phase 3 trial tests whether adding the targeted drug cabozantinib to two immunotherapies (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 participants with intermediate- or poor-risk disease are randomly …

This study is testing a simple urine test called CxBladder to see if it can accurately detect when bladder cancer comes back. Currently, patients need a camera inserted into the bladder (cystoscopy) for monitoring, which is uncomfortable and costly. The study will collect urine s…

This study is testing a new, non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have microscopic blood in their urine. Currently, these patients often need a cystoscopy, an invasive procedure where a camera is inse…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This study looks at whether a test that checks for a specific gene marker (SIX6) in urine or tissue can predict if bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had low-risk bladder cancer to see if the test can tell who is …

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…

This trial is developing a new, non-invasive urine test for bladder cancer. It uses a microfluidic chip to isolate tiny particles called exosomes from urine and analyze their genetic and protein content. The goal is to create a diagnostic model that can detect bladder cancer accu…

This study tests whether a new type of PET scan using a radioactive antibody called 124I-cG250 can detect if kidney cancer is responding to targeted therapy (sunitinib or pazopanib) earlier than standard CT scans. The antibody attaches to a protein found on kidney cancer cells, m…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study planned to test a special PET-CT scan (68Ga-PSMA) in people newly diagnosed with advanced kidney cancer. The goal was to see if it could find small cancer spots that standard scans miss. However, the trial was withdrawn before any patients were enrolled, so no results …

This program gives patients with kidney masses access to a radioactive tracer called 89Zr-DFO-girentuximab, which is used with a PET/CT scan to detect clear cell renal cell carcinoma (a common kidney cancer) without surgery. The tracer attaches to a protein (CAIX) often found on …

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…

This study compares two CT urography methods for diagnosing urothelial carcinoma (a type of urinary tract cancer). 352 adults with blood in urine or a history of this cancer will be randomly assigned to receive either a single-bolus or split-bolus CT scan. Researchers will compar…

This study tests whether a special MRI can tell the difference between harmless and cancerous kidney growths when standard CT scans cannot see fat. About 44 adults with kidney masses that have no visible fat on CT will get this advanced MRI. The goal is to see if the MRI can iden…

This study tests whether a special type of scan called SPECT/CT can help doctors make better decisions about treating kidney tumors. The scan uses a radioactive tracer to see how tumors behave. Researchers will check if the scan changes what doctors recommend for 102 patients wit…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctor…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …

This study aimed to see if a special PET/CT scan using a radioactive tracer called piflufolastat F 18 could better detect whether clear cell renal cell carcinoma (a type of kidney cancer) has spread. Researchers planned to enroll adults with suspected or high-risk metastatic dise…

This study tests whether new types of MRI scans can tell the difference between aggressive and harmless kidney tumors before surgery. Currently, standard scans can find tumors but can't tell if they are dangerous. 30 adults with small kidney tumors will get an extra MRI before th…

This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one …

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests a program of exercise, protein drinks, and mind-body activities like yoga for people aged 65 and older with advanced ovarian or pancreatic cancer. The goal is to see if patients can stick with the program while on chemotherapy before surgery. The study is small, …

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This trial tests whether one month of prehabilitation, including a health assessment, home exercise, and smoking cessation support, helps adults aged 65 and older recover more quickly from kidney tumor surgery. Half the participants receive this program before surgery, while the …

This trial tests a special education and navigation program for people with advanced bladder cancer and their caregivers. The program provides guidance, nutritional advice, and distress screening to help them better manage treatment decisions and care coordination. Researchers ho…

This trial tests whether a home-based telemonitoring program, which tracks symptoms and daily steps using a wearable device and app, can improve recovery and reduce complications within 30 days after abdominal surgery for gastrointestinal, genitourinary, or gynecologic cancers. P…

This study is testing whether a smartphone app that teaches mindfulness can help people with advanced kidney cancer cope with their illness. The trial will enroll 21 patients who are already receiving immunotherapy and have moderate to high fear of their cancer returning. The mai…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tested a program to help bladder cancer patients recover better after bladder removal surgery. The program included extra monitoring and support before, during, and after the operation to catch problems early. The goal was to reduce complications within 90 days after s…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based …

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study reviewed health records of 40,000 men in Ontario, Canada, to see if those who had kidney cancer surgery (nephrectomy) were more likely to develop a hydrocele—a fluid-filled sac in the scrotum. Researchers compared men who had laparoscopic or open surgery to similar men…

This study follows children and adults with medullary thyroid cancer (MTC), often linked to a genetic condition called MEN2. Researchers will track how the cancer grows and affects health over time using regular check-ups, blood tests, and imaging. No treatment is given, but part…

This study looks at whether wearable fitness trackers like the Fitbit Sense 2 can help doctors spot early signs of complications in patients recovering from bladder removal surgery. Fifty participants will wear the device and answer daily surveys for up to two weeks before surger…

This study looks at how immune cells change in the blood of people with kidney or bladder cancer during immunotherapy treatment. Researchers will measure different immune cells and tumor cells in blood samples from 67 participants. The goal is to better understand how the immune …

This study observes 224 adults with advanced or metastatic kidney cancer who are taking cabozantinib alone or with nivolumab as their first treatment. Researchers track how often doses are reduced, paused, or stopped due to side effects in everyday medical practice. The goal is t…

This study tracks how 150 patients in Belgium use the drug cabozantinib (Cabometyx), alone or with nivolumab, for advanced or metastatic kidney cancer. It looks at real-world dosing, treatment changes, and quality of life. The goal is to understand how these treatments are actual…

This study tests a special PET/CT scan that uses a radioactive tracer to see if it can predict how kidney cancer patients will respond to immunotherapy. The trial involves 46 participants with either localized or advanced kidney cancer. Researchers will compare scan results with …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study aims to identify the bacteria and fungi living in the urinary tract of people with calcium oxalate kidney stones or kidney cancer. Researchers will compare these microbial communities to those in healthy volunteers. The goal is to better understand how these tiny organ…

This study follows 200 bladder cancer patients who have had their bladder removed (cystectomy) to understand their information needs and how rehabilitation support can be improved. Researchers will track patients over time to see what help they need and how well they cope. The go…

This study creates a large registry of people with and without urothelial cancer (bladder, ureter, or renal pelvis cancer) to learn how genes and lifestyle affect risk. Participants provide a saliva sample and fill out questionnaires. The goal is to improve prevention, diagnosis,…

This study aims to collect and analyze genetic and clinical information from up to one million people with prostate, bladder, or kidney cancer. The goal is to better understand tumor biology and how this information can be used to improve treatment decisions and outcomes. Partici…

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study follows 468 people with metastatic kidney cancer to see how their treatment and quality of life change over time in real-world clinics. Researchers will track medication adherence, symptoms, and well-being using patient questionnaires. The goal is to understand what ac…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study looks at whether combining CT scan images, tumor features, and patient health information can better predict how well people recover after partial nephrectomy for endophytic kidney cancer. Researchers will analyze data from 406 patients who have already had surgery to …

This study tracks people who have had or will have a procedure called ablation to destroy kidney tumors. Researchers want to see how effective the procedure is and whether it improves patients' quality of life. Participants fill out questionnaires about their health and well-bein…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study follows 550 people with bladder cancer to understand how treatments like surgery affect their quality of life. Researchers want to learn what patients go through so doctors can offer better support and clearer information. The goal is to improve care, not to test a new…

This study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to s…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This early-stage study tests a tiny implantable device that releases very small amounts of several cancer drugs directly into bladder tumors. The goal is to see if the device is safe and can help doctors figure out which drugs kill the tumor best. Only 18 people with muscle-invas…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study aims to understand why kidney tumors in people with VHL syndrome can be different from each other. Researchers will use advanced imaging, multiple biopsies, and lab-grown tumor models to map these differences. The goal is to learn more about the disease, not to test a …

This study explores whether having kidney cancer patients report their side effects weekly through a short survey can help doctors manage those side effects better. The surveys ask about symptoms like nausea and fatigue and are sent directly to the care team, who then follow up i…

This study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…

This study is not testing a new drug, but rather doing the early science needed to develop one. Researchers are looking for the right targets (antigens) on adrenocortical carcinoma cells and studying how the tumor suppresses the immune system. The goal is to find a way to create …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study uses special MRI scans to look at kidney tumors in 39 people scheduled for surgery. The goal is to see if these scans can tell whether a tumor is cancerous and what type it is, as well as predict how well the kidney will work after part of it is removed. No new treatme…

This study follows 400 people with adrenocortical carcinoma who are taking mitotane as their first treatment. The goal is to carefully record all side effects, including ones that are not well understood. By collecting this data, researchers hope to improve how side effects are m…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study follows 600 people with non-muscle invasive bladder cancer to see how changes in smoking habits and body weight after diagnosis affect the chance of cancer coming back. Participants fill out questionnaires and provide saliva or urine samples over time. The goal is to l…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study looks at blood samples from 25 cancer patients receiving radiation therapy. Researchers want to find specific genes that show how each person's body responds to radiation. The goal is to better understand individual reactions and possibly personalize radiation treatmen…

This study is looking at two substances in the blood, called MMP2 and MMP9, to see if they can predict how well certain drugs work for people with advanced kidney cancer. Researchers will measure these markers in 50 patients who are starting treatment with Sunitinib or Pazopanib,…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study looks back at medical records from 1,000 people with adrenocortical carcinoma (ACC), a rare and serious cancer. Researchers want to see how factors like age, sex, race, and tumor burden relate to survival and treatment response. No new treatments are given; instead, th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study looks at how bladder cancer treatments affect people's quality of life years later. Researchers will ask 2000 patients in Denmark about their long-term side effects and what factors might make these worse. The goal is to better understand the real-life impact of treatm…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study looks at 100 people having laparoscopic kidney surgery to see if the carbon dioxide gas used to inflate the belly increases pressure inside the skull. Doctors will measure the optic nerve sheath diameter using ultrasound, a non-invasive way to check brain pressure. The…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study was designed to find out how often people develop hidden heart damage after kidney removal for cancer. Researchers planned to measure a blood marker of heart injury in 120 patients. However, the study was withdrawn before enrolling anyone, so no results are available.

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…